Stamford, Conn.-based Sema4, a genomics company spun out of Mount Sinai Health System, named former IBM leader Gustavo Stolovitzky, PhD, as its new chief scientific officer, the company said Sept. 13.
Dr. Stolovitzky brings more than 25 years of data analysis and biotechnology experience to his new position. Before joining Sema4, Dr. Stolovitzky spent 23 years at IBM Research, most recently serving as the founding chair of the exploratory life sciences program. Previously, he was director of IBM's translational systems biology and nanobiotechnology program.
In the new role of chief scientific officer, Dr. Stolovitzky will lead Sema4's research strategy and grow the company's partnerships with health systems and the biopharmaceutical industry.
New York City-based Mount Sinai spun its Genetic Testing Laboratory at the Icahn School of Medicine at Mount Sinai into Sema4 in June 2017. Earlier this year, the company completed its $500 million merger with special purpose acquisition company CM Life Sciences.